Showing results (561-570 of 701) with videos related to

Sort By:
Pageof 71
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2025
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trialMuthiah Vaduganathan, Jennifer B Green, Hiddo J L Heerspink, et al.
Cardiovascular Research|February 21, 2020
Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locusAnni A V Antikainen, Niina Sandholm, David-Alexandre Trégouët, et al.
Diabetes Care|September 19, 2025
Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, et al.
Diabetes, Obesity & Metabolism|May 5, 2026
Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup AnalysesDavid Z I Cherney, Peter Rossing, Maria Eugenia Canziani, et al.
Iscience|October 31, 2025
Current advances in diabetic neuropathy: Proteins as therapeutic targetsGurjeet Kaur, Salaha Osman Ali, Alberto Santos, et al.
Journal of Diabetes Research|July 15, 2015
Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular DysfunctionKarin G F Gerritsen, Jan Willem Leeuwis, Maarten P Koeners, et al.
Kidney Medicine|December 4, 2023
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD TrialsJohn M Flack, Rajiv Agarwal, Stefan D Anker, et al.
The New England Journal of Medicine|June 5, 2025
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 DiabetesRajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trialDavid C Wheeler, Bergur V Stefánsson, Niels Jongs, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup AnalysisPantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, et al.
Pageof 71